Google
×
This case underscores the importance of recognizing Tako-Tsubo cardiomyopathy in patients presenting with cardiogenic shock and highlights Levosimendan as a superior treatment option due to its beneficial effects on cardiac function and patient outcomes.
Aug 29, 2024
People also ask
The conclusion from this work was that there is “no clinical evidence that levosimendan produces vasopressor-resistant vasoplegic syndrome”. Levosimendan ...
Jan 3, 2020 · The initial management of TTS includes dual antiplatelet therapy, anticoagulants, beta-blockers, angiotensin-converting enzyme inhibitors or aldosterone ...
Missing: SOLUTION | Show results with:SOLUTION
Levosimendan, a non-catecholamine inotrope, a calcium sensitizer, and potassium channel opener, can be used among high-risk TTS patients with cardiogenic shock.
Missing: SAVING | Show results with:SAVING
Evidence suggests that levosimendan may be preferable to milrinone for patients in cardiogenic shock after cardiac surgery or for weaning from extracorporeal ...
Feb 5, 2008 · Treatment with β-blockade lowers heart rate and stroke volume, leading to frank shock. Decompensation may also occur when patients who are ...
Missing: SOLUTION | Show results with:SOLUTION
May 29, 2018 · Acute treatment. Takotsubo syndrome patients with cardiogenic shock, in particular those with apical ballooning should be promptly evaluated ...
Missing: SOLUTION | Show results with:SOLUTION
Management of takotsubo syndrome (TTS) is currently empirical and supportive, via extrapolation of therapeutic principles worked out for other cardiovascular ...
Missing: SAVING | Show results with:SAVING
Levosimendan is an inodilator that promotes cardiac contractility primarily through calcium sensitization of cardiac troponin C and vasodilatation.
Emergency veno-arterial extracorporeal membrane oxygenation, levosimendan, and noradrenaline transiently restored adequate systemic perfusion and gas exchange.